By contrast and as observed in ovarian cancer, a subset of patients derived clinical benefit of this combination irrespective of BRCA1/2-gene or PD-L1 status [289], again stressing the need to identify specific biomarkers of response for such combinations. This evidence concerns the gene BRCA1 and ovarian cancer.